Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary Fibrosis

Completed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Idiopathic Pulmonary Fibrosis

In brief

Endothelin-1 (ET-1) is expressed in a variety of pulmonary pathological conditions including pulmonary vascular disease and pulmonary fibrosis. Bosentan (an oral dual ET-1 receptor antagonist) could delay the progression of idiopathic pulmonary fibrosis (IPF), a condition for which no established treatment is available. The present trial investigates a possible use of bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH) WHO class III and IV, to a new category of patients suffering from IPF. It was decided to offer Open Label treatment (bosentan) for patients willing to continue in the BUILD 1 study.

Key facts

Study ID

NCT00071461

Run by

Actelion

People needed

158

Starts

2003-08-01

Expected to finish

2010-05-01

Last updated by the study team

2012-02-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female patients over 18 years of age.
• Women must be either postmenopausal (i.e., amenorrhea for at least 1 year), or surgically or naturally sterile.
• Women of childbearing potential must have a negative pre-treatment pregnancy test and use a reliable method of contraception during study treatment and for at least 3 months after study treatment termination.
• IPF proven diagnosis < 3 years documented according to ATS/ERS international multidisciplinary consensus, with or without surgical (thoracoscopic or open) chest lung biopsy
• Duration of illness ≥ 3 months.
• Six-minute walk test distance (limited by dyspnea) ≥ 150 meters and < 500 meters
• Patients who have signed the informed consent form prior to initiation of any study procedure.

You may not qualify if…

• Interstitial lung disease due to conditions other than IPF, including but not limited to radiation, sarcoidosis, hypersensitivity pneumonitis, bronchiolitis obliterans with organizing pneumonia, and cancer.
• History of clinically significant environmental exposure known to cause pulmonary fibrosis (drugs, asbestos, beryllium, radiation, domestic birds, etc.).
• Severe concomitant illness limiting life expectancy (< 1 year).
• FVC ≥ 90% predicted.
• Severe restrictive lung disease: FVC < 50% predicted or FVC < 1.2 l, or DLco < 30% predicted or residual volume ≥ 120% predicted.
• Severe obstructive lung disease: FEV1/FVC< 0.65.
• Documented improvement of patient's condition within 12 months prior to randomization with or without IPF-specific therapy (e.g., corticosteroids, immunosuppressive, cytotoxic or antifibrotic drugs, TNFa blocker, interferon g).
• Recent pulmonary or upper respiratory track infection (within 4 weeks of randomization).
• PaO2 < 55 mm Hg (sea level) or 50 mm Hg (altitude) at rest on room air.
• Echocardiographic evidence of severe pulmonary hypertension (PH): systolic pulmonary pressure ≥ 50 mm Hg or tricuspid regurgitation velocity ≥ 3.2 m/sec (unless severe PH is invalidated by a right heart catheterization). If the pulmonary pressure is not quantifiable, presence of significant right ventricular enlargement or hypertrophy or right ventricular dysfunction.
• Severe chronic heart failure, e.g., NYHA class III or IV and/or left ventricular ejection fraction < 25%.
• Acute or chronic impairment (other than dyspnea) limiting the ability to comply with study requirements, e.g., the 6MWT or the PFTs.
• (e.g., angina pectoris, intermittent claudicating, chronic arthritis).
• Baseline values of liver transaminases, i.e., aspartate aminotransferases (AST) and/or alanine aminotransferases (ALT) > 3 times the upper limit of normal ranges.
• Moderate to severe hepatic impairment, i.e., Child-Pugh Class B or C.
• Serum creatinine ≥ 2.5 mg/dl (221 mmol/l) or dialysis.
• Hemoglobin concentration < 75% the lower limit of normal ranges.
• Systolic blood pressure < 85 mm Hg.
• Pregnancy or breast-feeding.
• Current drug or alcohol dependence.
• Smoker (≥ 5 cigarettes per day) or former smoker (≥ 5 cigarettes per day) having stopped less than 6 months prior to randomization.
• Recently started (< 8 weeks from Screening visit) or planned cardio-pulmonary rehabilitation program based on exercise.
• Treatment with oral corticosteroids (> 15 mg/day prednisone or equivalent), immunosuppressive, cytotoxic or antifibrotic drugs such as TNF alpha blocker, or interferon gamma within 4 weeks of randomization.within 4 weeks of randomization.
• Treatment with glibenclamide (glyburide), cyclosporine A or tacrolimus within 1 weeks of randomization.
• Treatment with an endothelin receptor antagonist within 3 months of randomization.

Where it is running

• University of Alabama at Birmingham - Pulmonary Division — Birmingham, Alabama, United States
• David Geffen School of Medicine at UCLA - Division of Pulmonary and Critical Care Medicine — Los Angeles, California, United States
• UCSD Medical Center — San Diego, California, United States
• University of California - Ambulatory Care Center — San Francisco, California, United States
• National Jewish Medical and Research Center — Denver, Colorado, United States
• Yale University School of Medicine — New Haven, Connecticut, United States
• Jackson Memorial Hospital — Miami, Florida, United States
• University of Iowa Hospitals & Clinics - Department of Internal Medicine — Iowa City, Iowa, United States
• University of Michigan Health System - Division of Pulmonary & Critical Care Medicine — Ann Arbor, Michigan, United States
• Mayo Medical School - Mayo Clinic — Rochester, Minnesota, United States
• University of Pennsylvania — Philadelphia, Pennsylvania, United States
• University of Pittsburgh — Pittsburgh, Pennsylvania, United States
• Vanderbilt University Medical Center — Nashville, Tennessee, United States
• Baylor College of Medicine — Houston, Texas, United States
• University of Washington - Division of Pulmonary & Critical Care Medicine — Seattle, Washington, United States
• University of Wisconsin Hospitals & Clinics - Section of Pulmonary and Critical Care Medicine — Madison, Wisconsin, United States
• University of British Columbia - St. Paul's Hospital — Vancouver, British Columbia, Canada
• Rosedale Medical Center — Toronto, Ontario, Canada
• Notre-Dame Hospital - Clinique du Thorax — Montreal, Quebec, Canada
• Hôpital Avicenne - Université de Paris — Bobigny, France
• Médecine Spécialisée Aigüe - CHU Grenoble — Grenoble, France
• Hôpital Louis Pradel — Lyon, France
• Abt. Pneumologie Medizinische Klinik Universitätsklinikum Freiburg — Freiburg im Breisgau, Germany
• Klinik Löwenstein gGmbH — Löwenstein, Germany
• Medizinische Klinik und Poliklinik I Klinikum der Universität München — München, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.